Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell Lines

SIMPLE SUMMARY: Temozolomide (TMZ) is the first-line drug for chemotherapy of GBM, the most aggressive and incurable brain tumor. Acquired chemoresistance is a hallmark that causes the poor prognosis of GBM. Therefore, understanding the underlying mechanisms by using a proper model becomes emergent....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yuan, Chen, Zhen, Kim, Su Na, Gan, Chao, Ryl, Tatsiana, Lesjak, Michaela Silvia, Rodemerk, Jan, Zhong, Rong De, Wrede, Karsten, Dammann, Philipp, Sure, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101568/
https://www.ncbi.nlm.nih.gov/pubmed/35565340
http://dx.doi.org/10.3390/cancers14092211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101568/
https://www.ncbi.nlm.nih.gov/pubmed/35565340
http://dx.doi.org/10.3390/cancers14092211

Ejemplares similares